In vitro survival of MCF-7 breast cancer cells following combined treatment with ionizing radiation and mitoxantrone-mediated photodynamic therapy

被引:34
作者
Sazgarnia, Ameneh [1 ]
Montazerabadi, Ali Reza [2 ]
Bahreyni-Toosi, Mohammad Hossein [1 ]
Ahmadi, Amirhossein [3 ]
Aledavood, Amir [4 ]
机构
[1] Mashhad Univ Med Sci, Dept Med Phys, Res Ctr Med Phys, Mashhad, Iran
[2] Univ Tehran Med Sci, Dept Med Phys, Tehran, Iran
[3] Mazandaran Univ Med Sci, Fac Pharm, Pharmaceut Sci Res Ctr, Sari, Iran
[4] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran
关键词
Ionizing radiation; Photodynamic therapy; Mitoxantrone; MCF-7 breast cancer; TOPOISOMERASE-II-INHIBITORS; DOUBLE-STRAND BREAKS; NORMAL TISSUE; CYCLE PHASE; DNA; AMETANTRONE; MECHANISM; CHEMOTHERAPY; EXPOSURE; H2AX;
D O I
10.1016/j.pdpdt.2012.06.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study evaluated the effects of mitoxantrone (MX) as a sensitizer following combined treatment with ionizing radiation and photodynamic therapy in the MCF-7 human breast cancer cell line. Cells were incubated with MX at different concentrations for 90 min and exposed to different fluence rates of non-coherent light and different dose rates of ionizing X-ray radiation in independent treatment groups. Additionally, the combined effects of chemotherapy, phototherapy, and radiotherapy were evaluated. The percent cell survival was investigated using the MIT assay. MX acted as both a photosensitizer and radiosensitizer. Furthermore, the use of 1 mu M MX in combination with PDT at 10 J/Cm-2 and 4 Gy of X-ray radiation strongly resulted in the death of cancer cells and reduced the percentage of viable cancer cells to 2.4 +/- 1.15. Our data demonstrated that the adverse effects of MX in combination with radiotherapy were partially abated, without a reduction in the efficacy of treatment. This new therapeutic avenue for breast cancer therapy merits further investigation using in vivo models for application in humans. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:72 / 78
页数:7
相关论文
共 60 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Combining systemic therapies with radiation in breast cancer [J].
Adamowicz, Krzysztof ;
Marczewska, Malgorzata ;
Jassem, Jacek .
CANCER TREATMENT REVIEWS, 2009, 35 (05) :409-416
[3]   Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies [J].
Azarova, Anna M. ;
Lyu, Yi Lisa ;
Lin, Chao-Po ;
Tsai, Yuan-Chin ;
Lau, Johnson Yiu-Nam ;
Wang, James C. ;
Liu, Leroy F. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (26) :11014-11019
[4]   Optical properties of human skin, subcutaneous and mucous tissues in the wavelength range from 400 to 2000 nm [J].
Bashkatov, AN ;
Genina, EA ;
Kochubey, VI ;
Tuchin, VV .
JOURNAL OF PHYSICS D-APPLIED PHYSICS, 2005, 38 (15) :2543-2555
[5]  
BENJAMIN RS, 1995, SEMIN ONCOL, V22, P11
[6]   Structure of DNA topoisomerases [J].
Berger, JM .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :3-18
[7]  
BLANZ J, 1991, DRUG METAB DISPOS, V19, P871
[8]   The present and future role of photodynamic therapy in cancer treatment [J].
Brown, SB ;
Brown, EA ;
Walker, I .
LANCET ONCOLOGY, 2004, 5 (08) :497-508
[9]  
Bump E A., 1998, Radioprotectors: Chemical, biological and clinical perspective
[10]   Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme [J].
Burden, DA ;
Osheroff, N .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :139-154